Home | About us | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |   Login 
Pharmacognosy Reviews
Search Article 
Advanced search 
 Back To Article

  Reader Comments

Year : 2014 | Volume:  8 | Issue Number:  16


Cytotoxicity of dietary flavonoids on different human cancer types

Sak Katrin

Add Your Comments
1 Miguel Lopez-Lazaro, 8/28/2014 4:07:34 PM
I have experience in the evaluation of the anticancer effects of dietary flavonoids and, in my opinion, the cancer therapeutic potential of these compounds is low.

We typically assess in vitro therapeutic potential following a cytotoxic potency-based approach: the lower the concentration required to kill cancer cells, the higher the potential for cancer therapy (I have followed this approach many times in the past). However, despite its widespread use, this approach does not make much sense and is unreliable.

It does not make much sense because the aim of this approach is to find something that we do not need. Cancer patients do not need drugs that kill their cancer cells at low concentrations. They need drugs that kill their cancer cells at concentrations that do not significantly affect their normal cells; otherwise, the maximum doses tolerated by the patients will be insufficient to reach the drug concentrations required to eliminate the cancer cells from their bodies.

It is unreliable because the ability of a compound to kill cancer cells at low concentrations is not related to its ability to kill cancer cells selectively. Therefore, when we show that our compounds kill cancer cells at low concentrations, we are not revealing whether or not they have potential for cancer therapy.

To properly reveal the in vitro therapeutic potential of a compound, we should answer the question: Can the compound improve the ability of the standard drugs to kill cancer cells without significantly affecting nonmalignant cells from appropriate tissues? To my knowledge, no dietary flavonoid has been shown to improve the selectivity of the standard anticancer drugs.

Lopez-Lazaro, M. Experimental Cancer Pharmacology for Researchers: At What Concentration Should my Drug Kill Cancer Cells so that it has Potential for Cancer Therapy? 2014, ASIN: B00MMO25NM http://www.amazon.com/dp/B00MMO25NM/